Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited in competition
WADA 2026: S6.A, non-specified, prohibited in competition. The future 2027 List retains this classification. [1] [2]
2026 and 2027 List, S6.A, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Documented exposure
A US enforcement announcement identifies phenylpiracetam, the name associated with fonturacetam in the WADA List among unapproved drugs sold online. It is evidence of a documented sales context, not a clinical trial or worldwide legal-status survey. [3]
- Current human therapeutic evidence and country-by-country authorization were not reviewed here.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16
- E2. FDA/DOJ. Arizona Company and CEO Sentenced for Illegal Distribution of Tianeptine and Other Drugs, including adrafinil/phenylpiracetam. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
FDA-hosted DOJ announcement, drug identities and online distribution
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.